| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 02/28/2002 | US20020025949 Anti-epileptogenic agents |
| 02/28/2002 | US20020025944 Use of clioquinol for the therapy of Alzheimer's disease |
| 02/28/2002 | US20020025924 Novel lipopeptides as antibacterial agents |
| 02/28/2002 | US20020025919 Antiviral linear polymers |
| 02/28/2002 | US20020025916 Naphthalimide compositions and uses thereof |
| 02/28/2002 | US20020025543 Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy |
| 02/28/2002 | US20020025516 Nrde |
| 02/28/2002 | US20020025350 Dietary supplements |
| 02/28/2002 | US20020025336 Applying a surfactant-based formulation to the hair, which is capable of attacking lipids of the nits for removing nits from hair |
| 02/28/2002 | US20020025327 Use of neurotoxin therapy for treatment of urologic and related disorders |
| 02/28/2002 | US20020025317 For therapy and prophylaxis of pathological condition associated with expression of Interelukin-12 and/or Interleukin-18, including excessive or inappropriate amounts of those cytokines |
| 02/28/2002 | US20020025314 Administering compound identical in nature to active principle to be eliminated in a homeopathic product to restore normal function to the perturbed pericellular transport systems |
| 02/28/2002 | US20020025297 Methods of screening agents for activity using teleosts |
| 02/28/2002 | DE10111815A1 Treatment of epilepsy, especially drug-resistant epilepsy, using agents reducing inhibition of potassium-coupled outward transport of chloride from nerve cells, e.g. propranolol |
| 02/28/2002 | DE10030318C1 Arzneimittelverpackung für die Eradikationstherapie Drug packaging for the eradication |
| 02/28/2002 | CA2452346A1 Method for the identification of agents that inhibit or promote cataracts and uses thereof |
| 02/28/2002 | CA2421062A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 02/28/2002 | CA2420274A1 Use of vitamin d derivatives as bone resorption inhibitors |
| 02/28/2002 | CA2420233A1 Method for identifying substances useful for treating inflammation using the response element to the i.kappa.b.alpha. ror receptor |
| 02/28/2002 | CA2420194A1 Use of a porous carrier |
| 02/28/2002 | CA2420193A1 Compositions and methods for the diagnosis and treatment of tumor |
| 02/28/2002 | CA2420190A1 Oral fast-melt dosage form of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2420179A1 Composition and method for inhibiting platelet aggregation |
| 02/28/2002 | CA2420154A1 Dental composition for hypersensitive teeth |
| 02/28/2002 | CA2419872A1 Identification of a human n-terminal acetyltransferase gene |
| 02/28/2002 | CA2419840A1 Treatment of hyperproliferative diseases |
| 02/28/2002 | CA2419592A1 Rapidly disintegrating oral formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2419454A1 Regulator gene and system useful for the diagnosis and therapy of osteoporosis |
| 02/28/2002 | CA2419310A1 Substituted piperidines as melanocortin receptor agonists |
| 02/28/2002 | CA2419274A1 Methods and compositions for treating ige-related disease using nnt-1 inhibitors |
| 02/28/2002 | CA2418730A1 Oral fast-melt formulation of a cyclooxygenase-2 inhibitor |
| 02/28/2002 | CA2418461A1 Method and compositions for promoting osteogenesis |
| 02/28/2002 | CA2417787A1 Lipid metabolism enzymes |
| 02/28/2002 | CA2417186A1 Microtubule-associated proteins and tubulins |
| 02/28/2002 | CA2416748A1 Improved specificity in treatment of diseases |
| 02/28/2002 | CA2415791A1 Treatment of wounds |
| 02/28/2002 | CA2415788A1 Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
| 02/28/2002 | CA2415182A1 Pyrazole compounds, pharmaceutical compositions, and methods for modulating or inhibiting erab or hadh2 activity |
| 02/28/2002 | CA2388061A1 Diagnosis and treatment of cardiovascular conditions |
| 02/28/2002 | CA2356058A1 Intermittent administration of a growth hormone secretagogue |
| 02/27/2002 | EP1182259A1 Pyruvate:NADP+ oxidoreductase and uses thereof |
| 02/27/2002 | EP1181954A2 Biphenyl-2-carboxylic acid-tetrahydro-isoquinolin-6-yl amide derivatives, their preparation and use as inhibitors of microsomal triglyceride transfer protein and/or apolipoprotein B (ApoB) secretion |
| 02/27/2002 | EP1181935A2 Agent for treating mental disorders associated with cerebrovascular disorders |
| 02/27/2002 | EP1181932A2 Therapeutic compositions comprising excess enantiomer of amlodipine |
| 02/27/2002 | EP1181931A2 Intraoral adhesive preparation |
| 02/27/2002 | EP1181929A2 Method of potentiating an immune response and compositions therefor |
| 02/27/2002 | EP1181388A2 Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus |
| 02/27/2002 | EP1181317A1 An integrin heterodimer and an alpha subunit thereof |
| 02/27/2002 | EP1181316A1 DNA ENCODING SNORF36a AND SNORF36b RECEPTORS |
| 02/27/2002 | EP1181312A1 Cytotoxic t-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy |
| 02/27/2002 | EP1181305A1 Methods of modulating activity of prokaryotic ribosomes |
| 02/27/2002 | EP1181304A1 Antiproliferative activity of g-righ oligonucleotides and method of using same to bind to nucleolin |
| 02/27/2002 | EP1181281A2 Novel carboxylic acid derivatives comprising aryl-substituted nitrogen heterocycles, their production and their use as endothelin receptor antagonists |
| 02/27/2002 | EP1181055A2 Enzyme-activated anti-tumor prodrug compounds |
| 02/27/2002 | EP1181050A1 Methods for preventing reactivation of latent virus and controlling virus replication |
| 02/27/2002 | EP1181048A1 A pharmaceutical formulation containing an inhibitor of carboxypeptidase u and a thrombin inhibitor |
| 02/27/2002 | EP1181043A2 Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
| 02/27/2002 | EP1181037A2 Asthma associated factors as targets for treating atopic allergies including asthma and related disorders |
| 02/27/2002 | EP1181034A2 Combinations of immunosuppressive agents for the treatment or prevention of graft rejections |
| 02/27/2002 | EP1181029A1 Balsam for the treatment of surface burns and chafing rashes |
| 02/27/2002 | EP1181027A2 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria |
| 02/27/2002 | EP1181016A1 Chemical compounds having ion channel blocking activity for the treatment ofimmune dysfunction |
| 02/27/2002 | EP1181014A1 HETEROCYCLIC CONTAINING BIPHENYL aP2 INHIBITORS AND METHOD |
| 02/27/2002 | EP1181013A1 Method and composition for the treatment of cancer |
| 02/27/2002 | EP1181011A1 Compositions and methods for treatment of staphylococcal infection |
| 02/27/2002 | EP1181001A2 Sunscreen composition containing sol-gel microcapsules |
| 02/27/2002 | EP1180944A1 Compositions containing creatine in suspension |
| 02/27/2002 | EP1180937A1 Strains of bacteriophage useful for rescuing patients infected with vancomycin-resistant enterococcus faecium |
| 02/27/2002 | EP1180932A1 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof |
| 02/27/2002 | EP0936918B1 Combination therapy for treatment of arthritic diseases |
| 02/27/2002 | EP0836380B1 Fgf9 as a specific ligand for fgfr3 |
| 02/27/2002 | EP0831887B1 Therapy using lymphotoxin and thrombopoietin |
| 02/27/2002 | CN1337953A New thryoid receptor ligands and process II |
| 02/27/2002 | CN1337883A Tumor necrosis factor antagonists and their use in endometriosis |
| 02/27/2002 | CN1337881A Use of phosphororganic compounds for the prophylactic and therapeutical treatment of infections |
| 02/27/2002 | CN1337880A HIV-1 mutation selecting from beta-2',3'-didehydro-2',3-dideoxy-5-fluorocytidine |
| 02/27/2002 | CN1337879A Use of angiotensin II receptor antagonists for treating acute myocardial infarction |
| 02/27/2002 | CN1337878A Methods for treating overian cancer, poly(phosphoester) compositions, and biodegradable articles for same |
| 02/27/2002 | CN1337850A Amide derivatives for antiangiogenic and/or antitumorgenic use |
| 02/27/2002 | CN1337269A Local therapeutic method for skin |
| 02/27/2002 | CN1079671C Combination treatment for inhibiting bone loss |
| 02/27/2002 | CN1079660C Miniming trichomadesis with anti-fungus compound and halogeno-anti-bacteria compound |
| 02/26/2002 | US6350858 A polypeptide involved in controlling phosphate retention; diagnosis and therapy for chronic kidney failure, end stage kidney disease, uremic bone disease, and cancer |
| 02/26/2002 | US6350857 Fifty-four homologue (ffh) from streptococcus pneumoniae |
| 02/26/2002 | US6350786 Complexes significantly increase the bioavailability of poorly soluble therapeutically active compounds |
| 02/26/2002 | US6350784 Phytochemicals, surfactant, folic acid, |
| 02/26/2002 | US6350782 Use of basic amino acids derivatives for lowering ceramide levels |
| 02/26/2002 | US6350769 Gaba alpha receptors mediate inhibition of T cell responses |
| 02/26/2002 | US6350603 Phosphodiesterase 10 |
| 02/26/2002 | US6350598 MurD |
| 02/26/2002 | US6350581 Tumor-associated antigen |
| 02/26/2002 | US6350467 Pharmaceutical preparations of glutathione and methods of administration thereof |
| 02/26/2002 | US6350464 Methods for treating ovarian cancer, poly (phosphoester) compositions, and biodegradable articles for same |
| 02/26/2002 | US6350446 Polypeptides with amino acid sequences for kidney failure |
| 02/26/2002 | US6349443 Bottle/nipple cleaning device |
| 02/26/2002 | CA2163535C Inhibition of hair growth |
| 02/21/2002 | WO2002014870A2 Use of antibodies against specific mhc-peptide complexes |
| 02/21/2002 | WO2002014554A2 The anti-neoplastic agent et-743 inhibits trans activation by sxr |
| 02/21/2002 | WO2002014536A2 Odulating multiple lineage kinase proteins |
| 02/21/2002 | WO2002014522A1 Pyruvate:nadp+ oxidoreductase and uses thereof |